5-HT7 receptor antagonists

Details 5-HT7 receptor antagonists 5-HT7 receptor antagonists

2011-03-22

2011-03-22

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S253090, C544S357000, C544S364000

Reexamination Certificate

active

07910588

ABSTRACT:
The present invention provides selective 5-HT7receptor antagonist compounds of Formula I and their use in the treatment of migraine:where A is —C(H)═ or —N═ and R1-7are as defined herein.

REFERENCES:
patent: 6465467 (2002-10-01), Nilsson et al.
patent: 1254905 (2003-12-01), None
patent: 2004/067703 (2004-08-01), None
patent: 2005/069794 (2004-08-01), None
patent: 2005/117883 (2005-12-01), None
Lepailleur, et al. J. Chem. Inf. Model 2005, 45, 1075-1081 Molecular Modeling Studies Focused on 5-HT7 versus 5-HT1A Selectivity. Discovery of Novel Phenylpyrrole Derivatives with High Affinity for 5-HT7 Receptors.
Terron J., European Journal of Pharmacology, 2002, 439, 1-11 “Is the 5-HT7 receptor involved in the pathogenesis and prophylactic treatment of migraine?”.
Hedlund, et al., Trends in Pharmacological Sciences, vol. 25, 9, 2004, “Functional, molecular and pharmacological advances in 5-HT7 receptor research”.
M. Leopoldo., Current Medicinal Chemistry, 11, 629-661, 2004, Serotonin7 Receptors (5-HT7Rs) and their Ligands.

Affiliated with

Also associated with

Rating

5-HT7 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5-HT7 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-HT7 receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2704859